<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0303256969
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2017
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ZYLORIC 100MG TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        ALLOPURINOL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Tablet Container
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        22
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="ASPEN Bad Oldesloe GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            ASPEN Bad Oldesloe GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ASPEN PHARMA TRADING LIMITED (APTL)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        M04AA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>1. What Zyloric is and what it is used for</strong><br />Zyloric contains the active substance allopurinol. This medicine belongs to a group of medicines called enzyme inhibitors, which control the speed at which certain chemical changes occur in your body.</p><p>Zyloric Tablets are used to treat conditions where too much uric acid is produced by your body such as: gout; certain types of kidney disease and kidney stones; cancer and some enzyme disorders which lead to the build-up of too much uric acid.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>2. What you need to know before you take Zyloric</strong></p><p><strong>Do not take Zyloric if:</strong></p><ul><li>&nbsp;you ever had an allergy (rash, itching, shortness of breath) to Zyloric, allopurinol or any of the other tablet ingredients listed in section 6 of this leaflet</li></ul><p>If you are not sure, check with your doctor first before taking the medicine.</p><p><strong>Warnings and precautions</strong><br />Talk to your doctor before taking Zyloric about/ if:</p><ul><li>&nbsp;you are suffering, or have you suffered, from liver or kidney disease</li><li>&nbsp;you are taking medicines (diuretics and/or a medicine called ACE inhibitors) for heart disease or high blood pressure</li><li>&nbsp;you are experiencing an acute attack of gout</li><li>&nbsp;you are of Han Chinese, African or Indian origin</li><li>&nbsp;you have thyroid problems.</li></ul><p>Take special care with Zyloric:</p><ul><li>&nbsp;if you have kidney stones.The kidney stones will become smaller and may have a small chance of entering and blocking your urinary tract</li><li>skin rashes have been reported in patients taking allopurinol. Frequently, the rash can involve ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These serious skin rashes are often preceded by influenza-like symptoms fever, headache, body ache (flu-like symptoms). The rash may progress to widespread blistering and peeling of the skin. If you develop a rash or these skin symptoms, stop taking allopurinol and contact your doctor immediately</li><li>&nbsp;if you have cancer or Lesch-Nyhan syndrome the amount of uric acid may increase in your urine. To prevent this, you need to assure to drink sufficiently to dilute your urine.</li></ul><p><strong>Children</strong><br />Use in children is rarely indicated, except in some types of cancer (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.</p><p><strong>Other medicines and Zyloric</strong><br />It is important to let your doctor know if you are taking any of the following drugs (please check with your doctor if you are not sure):</p><ul><li>&nbsp;medicines used to reduce your immune response (immunosuppressants) e.g. 6-mercaptopurine, azathioprine and cyclosporin</li><li>&nbsp;adenine arabinoside (vidarabine), used to treat herpes or chickenpox</li><li>&nbsp;other medicines to treat gout, such as probenecid</li><li>&nbsp;aspirin (or related drugs called salicylates)</li><li>&nbsp;chlorpropamide, used to treat diabetes</li><li>&nbsp;drugs which thin the blood (anticoagulants), such as warfarin</li><li>medicines used for fits (epilepsy), phenytoin</li><li>&nbsp;theophylline, used for breathing problems</li><li>antibiotics (ampicillin or amoxicillin)</li><li>drugs used for the treatment of cancer</li><li>didanosine, used to treat HIV infection</li><li>&nbsp;medicines for heart problems or high blood pressure such as ACE inhibitors or water tablets (diuretics).</li></ul><p><strong>Pregnancy and breast-feeding</strong><br />If you are pregnant, breast-feeding, think you might be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine. Do not take Zyloric tablets if you are breast-feeding.</p><p><strong>Driving and using machines</strong><br />Zyloric tablets may make some people drowsy or have problems with their coordination. Do not drive or operate machinery until you know how it affects you.</p><p><strong>Zyloric Tablets contain lactose</strong><br />If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before you take Zyloric tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>3.How to take Zyloric</strong><br />Always take this medicine exactly as your doctor has told you. Check with your doctor if you are not sure. The label on the pack will tell you how many tablets to take and how often to take them. If the label does not say or if you are not sure, ask your doctor or pharmacist.</p><p>The back of the Zyloric 300 mg tablet blister strip is marked with the days of the week to help check that you have taken a dose each day. Press your first tablet out through the foil marked with todays day - for example, if today is Tuesday, use one marked &#39;Tue&#39;; move on to the &#39;Wed&#39; tablet tomorrow, and so on. Follow the arrows and do not start another blister strip of tablets until the first is finished. You should then start a new blister strip, every two weeks, on the same day of the week that you started the first one.</p><p>The amount of Zyloric that people can take can be very different. Your doctor will decide on a dose of Zyloric that is right for you.</p><p>The usual starting dose is in the range 100 to 300 mg daily, which may be taken as a single dose, after a meal. The tablets should be taken with a glass of water to make swallowing easier. The dose may be increased up to 900 mg daily, depending on the severity of your condition.</p><p>Dosage higher than 300 mg should be given in divided doses not exceeding 300 mg at any one time.</p><p>If you are an older person or if you have reduced liver or kidney function, your doctor may prescribe a lower dose or to take it at longer intervals. If you have dialysis two or three times a week, your doctor may prescribe a dose of 300 or 400 mg which is to be taken straight after your dialysis.</p><p><strong>Use in children (under 15 years)</strong><br />The usual dose is in the range 100-400 mg daily.</p><p><strong>If you take more Zyloric than you should</strong><br />If you take too many tablets or someone else takes your medicine by mistake, tell your doctor at once or go to the hospital straight away. Take the medicine pack with you. Signs of an overdose may include nausea, vomiting, diarrhoea and dizziness.</p><p><strong>If you forget to take Zyloric</strong><br />If you forget to take a dose, take another one as soon as you remember. However, if it is nearly time for the next dose, skip the missed dose. Do not take a double dose to make up for the forgotten.</p><p><strong>If you stop taking Zyloric</strong><br />Do not stop taking your Zyloric Tablets unless your doctor tells you to.</p><p>If you have any further questions on the use of this medicine, ask your doctor, nurse or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>4. Possible side effects</strong><br />Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>Hypersensitivity</strong><br /><strong>Uncommon </strong>(may affect less than 1 in 100 people)<br />Check with your doctor <strong>immediately </strong>if you experience any of the following:</p><ul><li>&nbsp;a reaction of any kind such as flaking skin, boils or sore lips and mouth</li><li>&nbsp;or very rarely, sudden wheeziness, fluttering or tightness in the chest; collapse</li></ul><p><strong>Rare</strong> (may affect less than 1 in 1000 people)</p><ul><li>&nbsp;fever and chills, headache, aching muscles (flu-like symptoms) and generally feeling unwell</li><li>&nbsp;serious hypersensitivity reactions involving fever, skin rash, joint pain, abnormalities in blood and liver function tests (these may be signs of a multi-organ sensitivity disorder).</li><li>&nbsp;bleeding in the lips, eyes, mouth, nose or genitals.</li><li>any changes to your skin, for example; ulcers of the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes), widespread blisters or peeling.</li></ul><p>THESE SYMPTOMS MAY MEAN THAT YOU ARE ALLERGIC TO ZYLORIC. Do NOT take any more tablets unless your doctor tells you to do so.</p><p><strong>Other side effects</strong><br /><strong>Common</strong> (may affect less than 1 in 10 people)</p><ul><li>&nbsp;skin rash</li></ul><p><strong>Uncommon </strong>(may affect less than 1 in 100 people)</p><ul><li>&nbsp;feeling sick (nausea) or being sick (vomiting)</li><li>abnormal liver tests</li></ul><p><strong>Rare</strong> (may affect less than 1 in 1000 people)</p><ul><li>&nbsp;Liver problems such as liver inflammation.</li></ul><p><strong>Very rare</strong> (may affect less than less than 1 in 10.000 people)</p><ul><li>high temperature</li><li>&nbsp;blood in your urine (haematuria)</li><li>&nbsp;high levels of cholesterol in your blood (hyperlipidaemia)</li><li>&nbsp;a general feeling of being unwell or feeling weak</li><li>&nbsp;weakness, numbness, unsteadiness on your feet, feeling unable to move muscles (paralysis) or loss of consciousness</li><li>&nbsp;headache, dizziness, drowsiness or disturbance of vision</li><li>chest pain (angina), high blood pressure or a slow pulse</li><li>retention of fluid leading to swelling (oedema) particularly of the ankles</li><li>abnormal glucose metabolism (diabetes). Your doctor may wish to measure the level of sugar in your blood to help to decide if this is happening.</li><li>&nbsp;occasionally Zyloric tablets may affect your blood. Tell your doctor as soon as you can if you notice that you are bruising more easily than usual, or if you develop a sore throat or other signs of an infection. These effects usually occur in people with liver or kidney problems.</li><li>&nbsp;Zyloric may affect the lymph nodes</li><li>male infertility, impotence</li><li>&nbsp;enlargement of the breasts, in men as well as women</li><li>a change in your normal bowel habit</li><li>change in taste perception</li><li>cataracts</li><li>&nbsp;hair loss or discolouration</li><li>depression</li><li>&nbsp;lack of voluntary coordination of muscle movements (ataxia)</li><li>sensation of tingling, tickling, pricking or burning of skin (paraesthesia)</li></ul><p>If you experience any of these side effects, or if you notice any side effects not listed in this leaflet while you are taking Zyloric please tell your doctor or pharmacist at once.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>5. How to store Zyloric</strong></p><p>Keep this medicine out of the reach and sight of children.</p><p>Store below 25C.</p><p>Store your tablets in the original pack.</p><p>Do not take this medicine after the expiry date, which is stated on the blister and carton.The expiry date refers to the last date of the stated month on which the product can be used.</p><p>Return any unwanted tablets to your pharmacist. Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Zyloric contains:</strong><br />The active substance is allopurinol.<br />The other ingredients are: lactose monohydrate, maize starch, povidone and magnesium stearate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                What Zyloric looks like and contents of the pack
Zyloric 100 mg Tablets are white to off-white with the marking " Z1" and a single line scored on one side. Each tablet contains 100 mg of the active ingredient, allopurinol. Zyloric 100 mg Tablets come in blister strips of 28 or100 tablets.

Zyloric 300 mg Tablets are white to off-white with the marking " Z3" and a single line scored on one side. Each tablet contains 300 mg of the active ingredient, allopurinol. Zyloric 300 mg Tablets come in blister strips of 28 tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder and Manufacturer</strong></p><p><strong>Marketing Authorization Holder</strong><br />Aspen Pharma Trading Limited, 3016 Lake Drive, Citywest Business Campus, Dublin 24, Ireland.</p><p><strong>Manufacturer</strong><br />Aspen Bad Oldesloe GmbH, Industriestrasse 32-36, 23843 Bad Oldesloe, Germany.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in {November/ 2019}, version {2}
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p><strong>1. ما هو زيلوريك ولما يُستخدم</strong></p><p>يحتوي زيلوريك على المادة الفعالة الوبيورينول. ينتمي هذا الدواء إلى مجموعة أدوية تُدعى مثبطات الإنزيمات، التي تتحكم في سرعة بعض التغيرات الكيميائية في الجسم .</p><p>تُستخدم أقراص زيلوريك لعلاج الحالات التي يفرز فيها الجسم مقدارًا كبيرًا من حمض اليوريك مثل: النقرس؛ أنواع معينة من أمراض الكلى وحصى الكلى؛ السرطان وبعض اضطرابات الإنزيمات التي تؤدي إلى تراكم مقدار كبير للغاية من حمض اليوريك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>2.&nbsp;ما الذي تحتاج إلى معرفته قبل تناول زيلوريك</strong></p><p>لا تتناول زيلوريك في الحالات التالية :</p><p>*إذا سبق لك أن تعرضت للإصابة بالحساسية (الطفح الجلدي والحكة وضيق في التنفس) من زيلوريك أو الوبيورينول أو أي من المكونات الأخرى المذكورة في القسم 6 من هذه النشرة .</p><p>إذا كنت غير متأكد، فاستشر الطبيب أولا قبل تناول الدواء .</p><p><strong>التحذيرات والاحتياطات</strong><br />استشر الطبيب قبل تناول زيلوريك بشأن/إذا :</p><ul><li>كنت تعاني، أو قد عانيت، من أمراض الكبد أو الكلى</li><li>&nbsp;كنت تتناول أدوية (مدرات البول و/أو دواء يُسمى مثبطات ACE) لأمراض القلب أو ارتفاع ضغط الدم</li><li>&nbsp;كنت تعاني من نوبة نقرس حادة</li><li>&nbsp;كنت من أصول الهان الصينيين أو إفريقيًا أو هنديًا .</li><li>&nbsp;إذا كانت لديك مشاكل في الغدة الدرقية</li></ul><p>يجب توخي الحذر بشكل خاص عند تناول زيلوريك في الحالات التالية&nbsp;:</p><ul><li>&nbsp;إذا كانت لديك حصوات الكلى. سوف تصبح هذه الحصوات أصغر وهناك احتمال ضئيل أن تدخل الى المسالك البولية وتسدها .</li><li>&nbsp;قد تم الإبلاغ عن حالات ظهور طفح جلدي لدى المرضى الذين يتناولون الوبيورينول. وفي كثير من الأحيان، يمكن للطفح أن ينطوي على تقرحات في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة (احمرار وانتفاخ العينين). وغالبًا ما يسبق هذه الحالات الخطيرة من الطفح الجلدي أعراض تشبه الأنفلونزا مثل الحمى والصداع وآلام الجسم (مثل أعراض الأنفلونزا). قد يتطور الطفح الجلدي إلى تقرحات وتقشير الجلد على نطاق واسع .هذه التفاعلات الخطيرة يمكن أن تكون أكثر شيوعا في الأفراد ذوي الأصول الهان الصينية أو، التايلاندية أو الكورية، تزداد الخطورة في هؤلاء الأشخاص مع وجود مرض كلوي مزمن. إذا تعرضت للطفح الجلدي أو هذه الأعراض الجلدية، <strong>فتوقف عن تناول الوبيورينول واتصل بطبيبك على الفور .</strong></li><li>إذا كنت تعاني من السرطان أو متلازمة ليش-نيهان، فإن كمية حمض اليوريك قد تزيد في البول. لمنع هذا، تحتاج إلى التأكد من أنك تشرب قدرًا كافيًا من الماء لتخفيف البول .</li></ul><p><strong>الأطفال</strong><br />نادرًا ما يُوصف الدواء للاستخدام من قِبل الأطفال، باستثناء بعض حالات السرطان (لا سيما سرطان الدم) وبعض اضطرابات الإنزيمات مثل متلازمة ليش-نيهان .</p><p><strong>الأدوية الأخرى وزيلوريك</strong><br />من المهم أن تخبر طبيبك إذا كنت تتناول أيًا من الأدوية التالية (يُرجى التحقق مع الطبيب إذا كنت غير متأكد):</p><ul><li dir="rtl">&nbsp;الأدوية المستخدمة للحد من استجابة الجهاز المناعي لديك (كابتات المناعة) على سبيل المثال 6 -ميركابتوبورين وآزوثيوبرين وسيكلوسبورين</li><li dir="rtl">&nbsp;أدينين أرابينوزيد (فيدارابين)، الذي يُستخدم لعلاج القوباء أو جدري الماء</li><li dir="rtl">أدوية أخرى تُستخدم لعلاج النقرس، مثل البروبينسيد</li><li dir="rtl">&nbsp;الأسبرين (أو الأدوية ذات الصلة التي تُسمى الساليسيلات)</li><li dir="rtl">كلوربروباميد، الذي يُستخدم لعلاج مرض السكري</li><li dir="rtl">الأدوية التي ترقق الدم (مضادات التخثر)، مثل الوارفارين</li><li>الأدوية المستخدمة لعلاج النوبات (الصرع)، مثل الفينيتوين</li><li>&nbsp;الثيوفيلين، الذي يُستخدم لعلاج مشاكل التنفس</li><li>&nbsp;المضادات الحيوية (أمبيسلين أو أموكسيسيلين)</li><li>الأدوية المستخدمة لعلاج السرطان</li><li>&nbsp;ديدانوزين، الذي يُستخدم لعلاج فيروس نقص المناعة البشرية</li><li>&nbsp;الأدوية المستخدمة لعلاج مشاكل القلب أو ارتفاع ضغط الدم مثل مثبطات ACE أو الأقراص المائية (مدرات البول)</li></ul><p>إن التناول المتزامن لهيدروكسيد الألومنيوم قد يؤدي إلى ضعف تأثير الألوبيورينول. يجب أن يكون هناك فاصل زمني لا يقل عن 3 ساعات بين أخذ كلا الدواءين. مع إعطاء الوبيورينول و الأدوية السامة للخلايا(على سبيل المثال السيكلوفوسفاميد ، الدوكسوروبيسين ، البليومايسين ، بروكاربازين ، ألكيل الهالوجينيدات) ، يحدث خلل في الدم بشكل أكثر تكرارًا عندما يتم إعطاء هذه المواد الفعالة وحدها .</p><p>و بالتالي يجب فحص الدم على فترات منتظمة .</p><p><strong>الحمل والرضاعة الطبيعية</strong></p><p>إذا كنتِ حاملاً أو ترضعين طفلك رضاعة طبيعية أو تعتقدين أنك ربما تكونين حاملاً أو تخططين لإنجاب طفل، فاستشيري الطبيب أو الصيدلي قبل تناول هذا الدواء. يفرز الألوبيورينول في حليب الأم. لايوصى بتناول الألوبيورينول خلال الرضاعة الطبيعية.</p><p><strong>القيادة واستخدام الآلات</strong><br />قد تجعل أقراص زيلوريك بعض الأشخاص يشعرون بالنعاس أو التعرض لمشاكل بشأن القدرة على التنظيم. لا تقد السيارة أو تشغل الآلات حتى تعلم كيف يؤثر عليك .</p><p><strong>أقراص زيلوريك تحتوي على اللاكتوز</strong></p><p>إذا كان طبيبك قد أخبرك بأنك تعاني من عدم تحمل بعض السكريات، فاتصل بطبيبك قبل تناول أقراص زيلوريك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>3.كيف تتناول زيلوريك</strong><br />احرص دائما على تناول هذا الدواء بالضبط كما أخبرك الطبيب. استشر الطبيب إذا كنت غير متأكد. يخبرك الملصق الموجود على العبوة كم عدد الأقراص الذي ينبغي تناوله وكم مرة. إذا لم يشر الملصق إلى ذلك أو إذا كنت غير متأكد، فاسأل الطبيب أو الصيدلي .</p><p>يحتوي الجزء الخلفي من الشريط الفقاعي لأقراص زيلوريك 300 ملجم على أيام الاسبوع للمساعدة على التحقق من أنك تناولت جرعة كل يوم. اضغط على القرص الأول لإخراجه من الشريحة المحددة باسم اليوم - على سبيل المثال، إذا كان اليوم هو الثلاثاء، فاستخدم الشريحة التي عليها علامة (&rsquo;Tue&lsquo; الثلاثاء)، وانتقل إلى القرص الذي عليه علامة( &rsquo;Wed&lsquo; الأربعاء) غدًا وهكذا. اتبع الأسهم ولا تبدأ في استخدام شريط فقاعي من الأقراص حتى تنتهي من الأول. يجب بعد ذلك البدء في استخدام شريط فقاعي كل أسبوعين، في نفس اليوم من الأسبوع الذي بدأت فيه استخدام الشريط الأول .</p><p>ويمكن أن يختلف مقدار زيلوريك الذي يمكن أن يتناوله الأشخاص اختلافًا كبيرًا. سوف يقرر الطبيب جرعة زيلوريك المناسبة لك .</p><p>وتكون الجرعة الأولية المعتادة في نطاق 100 إلى 300 ملجم يوميًا، والتي قد تؤخذ كجرعة واحدة بعد إحدى الوجبات. يجب تناول الأقراص مع كوب من الماء لجعل عملية البلع أكثر سهولة. ويمكن زيادة الجرعة حتى 900 ملجم يوميًا، حسب حدة الحالة .</p><p>ويجب إعطاء الجرعة التي تكون أكبر من 300 ملجم في جرعات مقسمة لا تتجاوز 300 ملجم في أي مرة .</p><p>إذا كنت شخصًا كبيرًا في السن أو تعاني من انخفاض في وظائف الكبد أو الكلى، فقد يصف لك الطبيب جرعة أقل أو تتناول الجرعات على فترات زمنية أطول. إذا كنت تخضع لغسيل الكلى مرتين أو ثلاث مرات في الأسبوع، فقد يصف الطبيب جرعة من 300 أو 400 ملجم يتم أخذها مباشرة بعد غسيل الكلى.</p><p><strong>الاستخدام لدى الأطفال (دون سن 15 عامًا)</strong></p><p>تكون الجرعة المعتادة في نطاق 100 إلى 400 ملجم يوميًا .</p><p><strong>إذا تناولت زيلوريك بجرعة أكثر مما ينبغي</strong></p><p>إذا تناولت عددًا كبيرًا جدًا من الأقراص أو إذا تناول شخص ما آخر دواءك عن طريق الخطأ، فأخبر الطبيب على الفور أو اذهب إلى المستشفى مباشرة. خُذ عبوة الدواء معك. قد تشمل أعراض الجرعة الزائدة الغثيان والقيء والإسهال والدوار .</p><p><strong>إذا نسيت تناول زيلوريك</strong></p><p>إذا نسيت تناول إحدى الجرعات، فخذ جرعة أخرى في أقرب وقت ممكن عندما تتذكرها. ومع ذلك، إذا كان الوقت قريبًا من الجرعة التالية، فدعك من الجرعة الفائتة. لا تأخذ جرعة مزدوجة لتعويض الجرعة التي نسيتها .</p><p><strong>إذا توقفت عن تناول زيلوريك</strong></p><p>لا تتوقف عن تناول أقراص زيلوريك حتى يخبرك الطبيب بذلك .</p><p>إذا كانت لديك أسئلة إضافية بشأن استخدام هذا الدواء، فاستشر الطبيب أو الممرضة أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p><strong>4.الآثار الجانبية المحتملة</strong><br />مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنه ليس كل شخص يُصاب بهذه الآثار الجانبية .</p><p><strong>فرط الحساسية</strong></p><p><strong>الآثار الجانبية غير الشائعة</strong><strong> </strong>(قد تؤثر على أقل من 1 من بين كل 100 شخص)</p><p>استشر الطبيب على الفور إذا تعرضت لأي مما يلي :</p><ul><li>رد فعل من أي نوع مثل قشور الجلد أو الدمامل أو قروح الشفتين والفم</li><li>أو في حالات نادرة جدًا، صعوبة التنفس المفاجئة أو ضيق في الصدر؛ الهبوط</li></ul><p><strong>الآثار الجانبية النادرة</strong> (قد تؤثر على أقل من 1 من بين كل 1000 شخص)</p><ul><li>&nbsp;الحمى والرجفة والصداع وآلام العضلات (أعراض تشبه أعراض الانفلونزا) والشعور العام بالتوعك</li><li>&nbsp;تفاعلات فرط الحساسية الخطيرة التي تنطوي على الحمى و الطفح الجلدي وآلام المفاصل واضطرابات في الدم</li><li>&nbsp;النزيف في الشفتين والعينين والفم والأنف أو الأعضاء التناسلية .</li><li>&nbsp;أي تغيرات للجلد، على سبيل المثال : تقرحات في الفم والحلق والأنف والأعضاء التناسلية والتهاب الملتحمة (واحمرار وانتفاخ العينين) وظهور بثور أو قشور على نطاق واسع</li></ul><p>هذه الأعراض قد تعني أنك تعاني من الحساسية من دواء ز يلوريك. توقف عن تتناول المزيد من أقراص زيلوريك حتى يخبرك الطبيب بذلك .</p><p><strong>الآثار الجانبية الأخرى</strong></p><p><strong>الآثار الجانبية الشائعة</strong> (قد تؤثر على أقل من 1 من بين كل 10 أشخاص)</p><ul><li>&nbsp;الطفح الجلدي</li><li>&nbsp;زيادة مستويات هرمون تحفيز الغدة الدرقية في الدم</li></ul><p><strong>الآثار الجانبية غير الشائعة</strong> (قد تؤثر على أقل من 1 من بين كل 100 شخص)</p><ul><li>&nbsp;الشعور بالإعياء (الغثيان) أو الدخول في حالة المرض بالفعل (التقيؤ)</li><li>&nbsp;اختبارات الكبد غير طبيعية</li></ul><p><strong>الآثار الجانبية النادرة</strong> (قد تؤثر على أقل من 1 من بين كل 1000 شخص)</p><ul><li>مشاكل في الكبد مثل التهاب الكبد.</li></ul><p><strong>الآثار الجانبية النادرة جدًا</strong> (قد تؤثر على أقل من 1 من بين كل 10000 شخص)</p><ul><li>ارتفاع درجة الحرار ة</li><li>وجود دم في البول (البول الدموي)</li><li>ارتفاع مستويات الكولسترول في الدم (فرط شحوم الدم)</li><li>شعور عام بالإعياء أو الشعور بالضعف</li><li>&nbsp;الضعف أو خدر أو عدم الثبات على القدمين أو الشعور بعدم القدرة على تحريك العضلات (الشلل) أو فقدان الوعي</li><li>الصداع أو الدوخة أو النعاس أو اضطراب في الرؤية</li><li>&nbsp;ألم في الصدر (الذبحة الصدرية) أو ارتفاع ضغط الدم أو النبض البطيء</li><li>&nbsp;الاحتفاظ بالسوائل بما يؤدي إلى التورم (وذمة) ولا سيما في الكعبين</li><li>&nbsp;أيض الجلوكوز غير الطبيعي (السكري). قد يرغب الطبيب في قياس مستوى السكر في الدم لمعرفة ما إذا كان هذا يحدث .</li><li>&nbsp;في بعض الأحيان تؤثر أقراص زيلوريك على الدم، والتي يمكن أن تظهر كالكدمات بسهولة أكثر من المعتاد ، أو قد تتطور إلى التهاب في الحلق أو أي علامات أخرى للإصابة. هذه الآثار تحدث عادة في الأشخاص الذين يعانون من مشاكل في الكبد أو الكلى. أخبر طبيبك في أقرب وقت ممكن.</li><li>قد يؤثر زيلوريك على الغدد الليمفاوية</li><li>&nbsp;العقم عند الذكور والعجز</li><li>&nbsp;تضخم الثدي لدى الرجال وكذلك النساء</li><li>تغير في عادة التغوط الطبيعية</li><li>تغير في تذوق الطعام</li><li>&nbsp;إعتام عدسة العين</li><li>فقدان الشعر أو تغيير لونه</li><li>&nbsp;الاكتئاب</li><li>غياب التنسيق الطوعي لحركات العضلات (الترنح)</li><li>الإحساس بوخز خفيف أو دغدغة أو ثقوب أو حروق الجلد (مذل)</li></ul><p>إذا تعرضت لأي من هذه الآثار الجانبية، أو إذا لاحظت أيًا من الآثار الجانبية غير المذكورة في هذه النشرة أثناء تناول زيلوريك، فيُرجى إخبار الطبيب أو الصيدلي على الفور.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>5 كيفية تخزين زيلوريك</strong></p><p>احفظ هذا الدواء بعيدًا عن متناول ورؤية الأطفال .</p><p>يحفظ في درجة حرارة تقل عن ٢٥ درجة مئوية .</p><p>احفظ الأقراص في العبوة الأصلية .</p><p>لا تأخذ هذا الدواء بعد تاريخ انتهاء الصلاحية، المسجل على الشريط والعلبة. يشير تاريخ انتهاء الصلاحية إلى آخر تاريخ للشهر المذكور الذي يمكن فيه استخدام المنتج .</p><p>قم بإعادة أي أقراص غير مطلوبة إلى الصيدلي. لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. سوف تساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p><strong>ما الذي يحتويه دواء زيلوريك :</strong></p><p>المادة الفعالة هي الوبيورينول .</p><p>المكونات الأخرى هي: مونوهيدرات اللاكتوز ونشا الذرة والبوفيدون وستيرات المغنيسيوم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ماذا يشبه زيلوريك وما هي محتويات العبوة:</strong></p><p dir="RTL">أقراص زيلوريك 100 ملجم هي بيضاء أو بيضاء ضاربة إلى الصفرة مع علامة &quot;Z1&quot; وخط واحد على جانب واحد. يحتوي كل قرص زيلوريك على 100 ملجم من المادة الفعالة، الوبيورينول. تأتي أقراص زيلوريك 100 ملجم بأشرطة فقاعية تتكون من 50 أو 100 قرص.</p><p dir="RTL">أقراص زيلوريك 300 ملجم هي بيضاء أو بيضاء ضاربة إلى الصفرة مع علامة &quot;Z3&quot; وخط واحد على جانب واحد. يحتوي كل قرص زيلوريك على 300 ملجم من المادة الفعالة، الوبيورينول. تأتي أقراص زيلوريك 300 ملجم بأشرطة فقاعية تتكون من 28 قرصًا.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>صاحب حق التسويق والشركة المصنعة :</strong></p><p><strong>صاحب حق التسويق</strong><br />أسبن فارما تريدينج المحدودة<br />3016 ليك درايف<br />سيتي ويست بزنس كامبوس<br />دبلن 24<br />أيرلندا</p><p><strong>الشركة المصنعة</strong><br />أسبن باد أولسلو جي. إم. بي. إتش .<br />إندستريشتراس 32 - 36<br />D-23843 باد أولسلو<br />ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            تمت مراجعة هذه النشرة في {نوفمبر/ 2019}، النسخة {2}
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Zyloric 100 mg Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each tablet contains 100 mg of allopurinol.

Excipient(s) with known effect:
Each tablet also contains 50 mg of the excipient lactose monohydrate.
For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet.

Round, white to off-white biconvex, bisected tablets, debossed with Z1 on one side.

The score line is only to facilitate breaking for ease of swallowing and not to divide the tablet into equal doses.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zyloric is indicated for reducing urate/uric acid formation in conditions where urate/uric acid deposition has already occurred (e.g. gouty arthritis, skin tophi, nephrolithiasis) or is a predictable clinical risk (e.g. treatment of malignancy potentially leading to acute uric acid nephropathy).</p><p>The main clinical conditions where urate/uric acid deposition may occur are:</p><ul><li>&nbsp;Idiopathic gout;</li><li>Uric acid lithiasis;</li><li>Acute uric acid nephropathy;</li><li>&nbsp;Neoplastic disease and myeloproliferative disease with high cell turnover rates, in which high urate levels occur either spontaneously, or after cytotoxic therapy;</li><li>Certain enzyme disorders which lead to overproduction of urate, for example:</li></ul><p>&minus; Hypoxanthine-guanine phosphoribosyltransferase, including Lesch-Nyhan syndrome;<br />&minus; Glucose-6-phosphatase including glycogen storage disease;<br />&minus; Phosphoribosylpyrophosphate synthetase;<br />&minus; Phosphoribosylpyrophosphate amidotransferase;<br />&minus; Adenine phosphoribosyltransferase.</p><p>Zyloric is indicated for the management of 2,8-dihydroxyadenine (2,8-DHA) renal stones related to deficient activity of adenine phosphoribosyltranferase.</p><p>Zyloric is indicated for the management of recurrent mixed calcium oxalate renal stones in the presence of hyperuricosuria, when fluid, dietary and similar measures have failed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p><em><u>Adults</u></em></p><p>Zyloric should be introduced at low dosage e.g. 100 mg/day to reduce the risk of adverse reactions and increased only if the serum urate response is unsatisfactory. Extra caution should be exercised if renal function is poor (see section 4.2 Renal impairment). The following dosage schedules are suggested:</p><p>100 to 200 mg daily in mild conditions;<br />300 to 600 mg daily in moderately severe conditions;<br />700 to 900 mg daily in severe conditions.</p><p>Dosage higher than 300 mg should be given in divided doses not exceeding 300 mg at any time. If dosage on a mg/kg bodyweight basis is required, 2 to 10 mg/kg bodyweight/day should be used.<br />Paediatric population</p><p>Children under 15 years: 10 to 20 mg/kg bodyweight/day up to a maximum of 400 mg daily. Use in children is rarely indicated, except in malignant conditions (especially leukaemia) and certain enzyme disorders such as Lesch-Nyhan syndrome.</p><p><em>Older people</em></p><p>In the absence of specific data, the lowest dosage which produces satisfactory urate reduction should be used. Particular attention should be paid to advice in &ldquo;section 4.2 Renal impairment&rdquo; and section 4.4.</p><p><em>Renal impairment</em><br />Since allopurinol and its metabolites are excreted by the kidney, impaired renal function may lead to retention of the drug and/or its metabolites with consequent prolongation of plasma half-lives. In severe renal insufficiency, it may be advisable to use less than 100 mg per day or to use single doses of 100 mg at longer intervals than one day.</p><p>If facilities are available to monitor plasma oxipurinol concentrations, the dose should be adjusted to maintain plasma oxipurinollevels below 100 &mu;mol/litre (15.2 mg/litre).</p><p>Allopurinol and its metabolites are removed by renal dialysis. If dialysis is required two to three times a week consideration should be given to an alternative dosage schedule of 300-400 mg Zyloric immediately after each dialysis with none in the interim.</p><p><em>Hepatic impairment</em><br />Reduced doses should be used in patients with hepatic impairment. Periodic liver function tests are recommended during the early stages of therapy.</p><p><em>Treatment of high urate turnover conditions, e.g. neoplasia, Lesch-Nyhan syndrome</em></p><p>It is advisable to correct existing hyperuricaemia and/or hyperuricosuria with Zyloric before starting cytotoxic therapy. It is important to ensure adequate hydration to maintain optimum diuresis and to attempt alkalinisation of urine to increase solubility of urinary urate/uric acid. Dosage of Zyloric should be at the lower end of the recommended dosage schedule.</p><p>If urate nephropathy or other pathology has compromised renal function, the advice given in section 4.2 Renal impairment should be followed.</p><p>These steps may reduce the risk of xanthine and/or oxipurinol deposition complicating the clinical situation. See also section 4.5 and section 4.8</p><p><em>Monitoring Advice</em><br />The dosage should be adjusted by monitoring serum urate concentrations and urinary urate/uric acid levels at appropriate intervals.</p><p><u>Method of Administration</u></p><p>Zyloric may be taken orally once a day after a meal. It is well tolerated, especially after food. Should the daily dosage exceed 300 mg and gastrointestinal intolerance be manifested, a divided dose regimen may be appropriate.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hypersensitivity syndrome, SJS and TEN</u></p><p>Allopurinol hypersensitivity reactions can manifest in many different ways, including maculopapular exanthema, hypersensitivity syndrome (also known as DRESS) and Steven Johnson Syndrome (SJS) /toxic epidermal necrolysis (TEN). These reactions are clinical diagnoses, and their clinical presentations remain the basis for decision making. If such reactions occur at any time during treatment, allopurinol should be withdrawn<strong> immediately.</strong> Rechallenge should not be undertaken in patients with hypersensitivity syndrome and SJS/TEN. Corticosteroids may be beneficial in overcoming hypersensitivity skin reactions. (see section 4.8 Adverse Reactions- Immune system disorders and Skin and subcutaneous tissue disorders).</p><p><u>HLA-B*5801 allele</u></p><p>The HLA-B*5801 allele has been shown to be associated with the risk of developing allopurinol related hypersensitivity syndrome and SJS/TEN. The frequency of the HLA-B*5801 allele varies widely between ethnic populations: up to 20% in Han Chinese population, about 12% in the Korean population and 1-2% in individuals of Japanese or European origin. The use of genotyping as a screening tool to make decisions about treatment with allopurinol has not been established. If the patient is a known carrier of HLA-B*5801, the use of allopurinol may be considered if the benefits are thought to exceed risks. Extra vigilance for signs of hypersensitivity syndrome or SJS/TEN is required and the patient should be informed of the need to stop treatment immediately at the first appearance of symptoms.</p><p><u>Renal or hepatic impairment</u></p><p>Reduced doses should be used in patients with hepatic or renal impairment. Patients under treatment for hypertension or cardiac insufficiency, for example with diuretics or ACE inhibitors, may have some concomitant impairment of renal function and allopurinol should be used with care in this group.</p><p>Chronic renal insufficiency and concomitant diuretic use, in particular thiazides, has been associated with an increased risk of allopurinol induced SJS/TEN, and other serious hypersensitivity reactions.</p><p><u>Asymptomatic hyperuricaemia</u></p><p>Asymptomatic hyperuricaemia per se is generally not considered an indication for use of Zyloric. Fluid and dietary modification with management of the underlying cause may correct the condition.</p><p><u>Acute gouty attacks</u></p><p>Allopurinol treatment should not be started until an acute attack of gout has completely subsided, as further attacks may be precipitated.</p><p>In the early stages of treatment with Zyloric, as with uricosuric agents, an acute attack of gouty arthritis may be precipitated. Therefore it is advisable to give prophylaxis with a suitable anti-inflammatory agent or colchicine for at least one month. The literature should be consulted for details of appropriate dosage and precautions and warnings.</p><p>If acute attacks develop in patients receiving allopurinol, treatment should continue at the same dosage while the acute attack is treated with a suitable anti-inflammatory agent.</p><p><u>Xanthine deposition</u></p><p>In conditions where the rate of urate formation is greatly increased (e.g. malignant disease and its treatment, LeschNyhan Syndrome) the absolute concentration of xanthine in urine could, in rare cases, rise sufficiently to allow deposition in the urinary tract. This risk may be minimised by adequate hydration to achieve optimal urine dilution.</p><p><u>Impaction of uric acid renal stones</u><br />Adequate therapy with Zyloric will lead to dissolution of large uric acid renal pelvic stones, with the remote possibility of impaction in the ureter.</p><p><u>Thyroid disorders</u></p><p><u>Increased TSH values (&gt;5.5 &mu;IU/mL) were observed in patients on long-term treatment with allopurinol (5.8%) in a long term open label extension study.</u></p><p><u>Lactose</u></p><p>Patients with rare hereditary problems of galactose intolerance, the Lapp lactose deficiency or glucose-galactose malabsorption should not take this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>6-mercaptopurine and azathioprine</u></p><p>Azathioprine is metabolised to 6-mercaptopurine which is inactivated by the action of xanthine oxidase. When 6-mercaptopurine or azathioprine is given concurrently with Zyloric, only one-quarter of the usual dose of 6-mercaptopurine or azathioprine should be given because inhibition of xanthine oxidase will prolong their activity.</p><p><u>Vidarabine (Adenine Arabinoside)</u></p><p>Evidence suggests that the plasma half-life of vidarabine is increased in the presence of allopurinol. When the two products are used concomitantly extra vigilance is necessary, to recognise enhanced toxic effects.</p><p><u>Salicylates and uricosuric agents</u></p><p>Oxipurinol, the metabolite of allopurinol and itself therapeutically active, is excreted by the kidney&nbsp;in a similar way to urate. Hence, drugs with uricosuric activity such as probenecid or large doses of salicylate may accelerate the excretion of oxipurinol. This may decrease the therapeutic activity of Zyloric, but the significance needs to be assessed in each case.</p><p><u>Chlorpropamide</u><br />If Zyloric is given concomitantly with chlorpropamide when renal function is poor, there may be an increased risk of prolonged hypoglycaemic activity because allopurinol and chlorpropamide may compete for excretion in the renal tubule.</p><p><u>Coumarin anticoagulants</u><br />There have been rare reports of increased effect of warfarin and other coumarin anticoagulants when co-administered with allopurinol, therefore, all patients receiving anticoagulants must be carefully monitored.</p><p><u>Phenytoin</u></p><p>Allopurinol may inhibit hepatic oxidation of phenytoin but the clinical significance has not been demonstrated.</p><p><u>Theophylline</u></p><p>Inhibition of the metabolism of theophylline has been reported. The mechanism of the interaction may be explained by xanthine oxidase being involved in the biotransformation of theophylline in man. Theophylline levels should be monitored in patients starting or increasing allopurinol therapy.</p><p><u>Ampicillin/Amoxicillin</u><br />An increase in the frequency of skin rash has been reported among patients receiving ampicillin or amoxicillin concurrently with allopurinol compared to patients who are not receiving both drugs. The cause of the reported association has not been established. However, it is recommended that in patients receiving allopurinol an alternative to ampicillin or amoxicillin is used where available.</p><p><u>Cyclophosphamide, doxorubicin, bleomycin, procarbazine, mechloroethamine</u></p><p>Enhanced bone marrow suppression by cyclophosphamide and other cytotoxic agents has been reported among patients with neoplastic disease (other than leukaemia), in the presence of allopurinol. However, in a well-controlled study of patients treated with cyclophosphamide, doxorubicin, bleomycin, procarbazine and/or mechloroethamine (mustine hydrochloride) allopurinol did not appear to increase the toxic reaction of these cytotoxic agents.</p><p><u>Cyclosporin</u></p><p>Reports suggest that the plasma concentration of cyclosporin may be increased during concomitant treatment with allopurinol. The possibility of enhanced cyclosporin toxicity should be considered if the drugs are co-administered.</p><p><u>Didanosine</u></p><p>In healthy volunteers and HIV patients receiving didanosine, plasma didanosine Cmax and AUC values were approximately doubled with concomitant allopurinol treatment (300 mg daily) without affecting terminal half-life. Therefore, dose reductions of didanosine may be required when used concomitantly with allopurinol.</p><p><u>Diuretics</u></p><p>An interaction between allopurinol and furosemide that results in increased serum urate and plasma oxipurinol concentrations has been reported.<br />An increased risk of hypersensitivity has been reported when allopurinol is given with diuretics, in particular thiazides, especially in renal impairment.</p><p><u>Angiotensin-converting-enzyme (ACE) inhibitors.</u></p><p>An increased risk of hypersensitivity has been reported when allopurinol is given with ACE inhibitors especially in renal impairment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There is inadequate evidence of safety of Zyloric in human pregnancy, although it has been in wide use for many years without apparent ill consequence (see section 5.3).</p><p>Use in pregnancy only when there is no safer alternative and when the disease itself carries risks for the mother or unborn child.</p><p><u>Breast-feeding</u></p><p>Reports indicate that allopurinol and oxipurinol are excreted in human breast milk. Concentrations of 1.4 mg/litre allopurinol and 53.7 mg/litre oxipurinol have been demonstrated in breast milk from a woman taking Zyloric 300 mg/day. However, there are no data concerning the effects of allopurinol or its metabolites on the breast-fed baby. A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from allopurinol therapy taking into account the benefit of breast feeding for the child and the benefit of therapy for the woman.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Since adverse reactions such as somnolence, vertigo and ataxia have been reported in patients receiving allopurinol, patients should exercise caution before driving, using machinery or participating in dangerous activities until they are reasonably certain that allopurinol does not adversely affect performance.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For this product there is no modern clinical documentation which can be used as support for determining the frequency of undesirable effects. Undesirable effects may vary in their incidence depending on the dose received and also when given in combination with other therapeutic agents.</p><p>The frequency categories assigned to the adverse drug reactions below are estimates: for most reactions, suitable data for calculating incidence are not available. Adverse drug reactions identified through post-marketing surveillance were considered to be rare or very rare. The following convention has been used for the classification of frequency:</p><p>Very Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &ge;1/10<br />Common&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &ge;1/100 to &lt;1/10<br />Uncommon&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&ge;1/1,000 to &lt;1/100<br />Rare&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &ge;1/10,000 to &lt;1/1000<br />Very Rare&nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;&lt;1/10,000</p><p>Adverse reactions in association with allopurinol are rare in the overall treated population and&nbsp;mostly of a minor nature. The incidence is higher in the presence of renal and/or hepatic disorder.</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms and Signs</u></p><p>Ingestion of up to 22.5 g allopurinol without adverse effect has been reported. Symptoms and signs including nausea, vomiting, diarrhoea and dizziness have been reported in a patient who ingested 20 g allopurinol. Recovery followed general supportive measures.</p><p><u>Management</u><br />Massive absorption of Zyloric may lead to considerable inhibition of xanthine oxidase activity, which should have no untoward effects unless affecting concomitant medication especially with 6-mercaptopurine and/or azathioprine. Adequate hydration to maintain optimum diuresis facilitates excretion of allopurinol and its metabolites. If considered necessary haemodialysis may be used.</p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top; width:325px"><p><strong>System Organ Class </strong></p></td><td style="vertical-align:top; width:162px"><p><strong>Frequency </strong></p></td><td style="vertical-align:top; width:308px"><p><strong>Adverse reaction </strong></p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Infections and infestations</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Furuncle</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p><p>&nbsp;</p></td><td style="vertical-align:top; width:308px"><p>Agranulocytosis<sup>1</sup></p><p>Aplastic anaemia<sup>1</sup></p><p>Thrombocytopenia<sup>1</sup></p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:325px"><p>Immune system disorders</p></td><td style="vertical-align:top; width:162px"><p>Uncommon</p></td><td style="vertical-align:top; width:308px"><p>Hypersensitivity<sup>2</sup></p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Angioimmunoblastic T-cell lymphoma<sup>3</sup></p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Diabetes mellitus</p><p>Hyperlipidaemia</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Depression</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Nervous system disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Coma</p><p>Paralysis</p><p>Ataxia</p><p>Neuropathy peripheral</p><p>Paraesthesia</p><p>Somnolence</p><p>Headache</p><p>Dysgeusia</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Eye disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Cataract</p><p>Visual impairment</p><p>Maculopathy</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Vertigo</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Cardiac disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Angina pectoris</p><p>Bradycardia</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Vascular disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Hypertension</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:325px"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top; width:162px"><p>Uncommon</p></td><td style="vertical-align:top; width:308px"><p>Vomiting<sup>4</sup></p><p>Nausea<sup>4</sup></p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Haematemesis</p><p>Steatorrhoea</p><p>Stomatitis</p><p>Change of bowel habit</p></td></tr><tr><td rowspan="2" style="vertical-align:top; width:325px"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top; width:162px"><p>Uncommon</p></td><td style="vertical-align:top; width:308px"><p>Liver function test abnormal<sup>5</sup></p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Rare</p></td><td style="vertical-align:top; width:308px"><p>Hepatitis (including hepatic necrosis and granulomatous hepatitis)<sup>5</sup></p></td></tr><tr><td rowspan="3" style="vertical-align:top; width:325px"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:162px"><p>Common</p></td><td style="vertical-align:top; width:308px"><p>Rash</p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Rare</p></td><td style="vertical-align:top; width:308px"><p>Stevens-Johnson syndrome/toxic epidermal necrolysis<sup>6</sup></p></td></tr><tr><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Angioedema<sup>7</sup></p><p>Drug eruption</p><p>Alopecia</p><p>Hair colour changes</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Renal and urinary disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Haematuria</p><p>Azotaemia</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Infertility male</p><p>Erectile dysfunction</p><p>Gynaecomastia</p></td></tr><tr><td style="vertical-align:top; width:325px"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top; width:162px"><p>Very rare</p></td><td style="vertical-align:top; width:308px"><p>Oedema</p><p>Malaise</p><p>Asthenia</p><p>Pyrexia<sup>8</sup></p></td></tr></tbody></table><p>1. Very rare reports have been received of thrombocytopenia, agranulocytosis and aplastic anaemia, particularly in individuals with impaired renal and/or hepatic function, reinforcing&nbsp;the need for particular care in this group of patients.<br />2. A delayed multi-organ hypersensitivity disorder (known as hypersensitivity syndrome or DRESS) with fever, rashes, vasculitis, lymphadenopathy, pseudo lymphoma, arthralgia, leucopenia, eosinophilia hepato-splenomegaly, abnormal liver function tests, and vanishing bile duct syndrome (destruction and disappearance of the intrahepatic bile ducts) occurring in various combinations. Other organs may also be affected (e.g. liver, lungs, kidneys, pancreas, myocardium, and colon). If such reactions do occur, it may be at any time during treatment, allopurinol should be withdrawn IMMEDIATELY and PERMANENTLY.<br />Rechallenge should not be undertaken in patients with hypersensitivity syndrome and SJS/TEN. Corticosteroids may be beneficial in overcoming hypersensitivity skin reactions. When generalised hypersensitivity reactions have occurred, renal and/or hepatic disorder has usually been present particularly when the outcome has been fatal.<br />3. Angioimmunoblastic T-cell lymphoma has been described very rarely following biopsy of a generalised lymphadenopathy. It appears to be reversible on withdrawal of allopurinol.<br />4. In early clinical studies, nausea and vomiting were reported. Further reports suggest that this reaction is not a significant problem and can be avoided by taking allopurinol after meals.<br />5. Hepatic dysfunction has been reported without overt evidence of more generalised hypersensitivity.<br />6. Skin reactions are the most common reactions and may occur at any time during treatment. They may be pruritic, maculopapular, sometimes scaly, sometimes purpuric and rarely exfoliative, such as Stevens-Johnson syndrome and toxic epidermal necrolysis (SJS/TEN). Allopurinol should be withdrawn IMMEDIATELY should such reactions occur. The highest risk for SJS and TEN, or other serious hypersensitivity reactions, is within the first weeks of treatment. The best results in managing such reactions come from early diagnosis and immediate discontinuation of any suspect drug. After recovery from mild reactions, allopurinol may, if desired, be re-introduced at a small dose (e.g. 50 mg/day) and gradually increased. The HLA-B*5801 allele has been shown to be associated with the risk of developing allopurinol related hypersensitivity syndrome and SJS/TEN. The use of genotyping as a screening tool to make decisions about treatment with allopurinol has not been established. If the rash reoccurs, allopurinol should be PERMANENTLY withdrawn as more severe hypersensitivity reactions may occur (see section 4.8 Immune system disorders). If SJS/TEN, or other serious hypersensitivity reactions cannot be ruled out, DO NOT re-introduce allopurinol due to the potential for a severe or even fatal reaction. The clinical diagnosis of SJS/TEN, or other serious hypersensitivity reactions remain the basis for decision making.<br />7. Angioedema has been reported to occur with and without signs and symptoms of a more generalised allopurinol hypersensitivity reaction.<br />8. Fever has been reported to occur with and without signs and symptoms of a more generalised allopurinol hypersensitivity reaction (see section 4.8 Immune system disorders).</p><p><u>To reports any side effect(s):</u></p><p><strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>&bull; The National Pharmacovigilance Centre (NPC):<br />- SFDA Call Center: 19999<br />- E-mail: npc.drug@sfda.gov.sa<br />- Website: https://ade.sfda.gov.sa/</td></tr></tbody></table><p><strong>Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td>- Please contact the relevant competent authority.</td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Preparations inhibiting uric acid production</p><p>ATC Code: M04AA01</p><p><u>Mechanism of action</u></p><p>Allopurinol is a xanthine-oxidase inhibitor. Allopurinol and its main metabolite oxipurinol lower the level of uric acid in plasma and urine by inhibition of xanthine oxidase, the enzyme catalyzing the oxidation of hypoxanthine to xanthine and xanthine to uric acid.</p><p><u>Pharmacodynamic effects</u></p><p>In addition of the inhibition of purine catabolism, in some but not all hyperuricaemic patients, de novo purine biosynthesis is depressed via feedback inhibition of hypoxanthine-guanine phosphoribosyltransferase. Other metabolites of allopurinol include allopurinol-riboside and oxipurinol-7-riboside.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Allopurinol is active when given orally and is rapidly absorbed from the upper gastrointestinal tract. Studies have detected allopurinol in the blood 30-60 minutes after dosing. Estimates of bioavailability vary from 67% to 90%.</p><p>Peak plasma levels of allopurinol generally occur approximately 1.5 hours after oral administration of Zyloric, but fall rapidly and are barely detectable after 6 hours. Peak plasma levels of oxipurinol generally occur after 3-5 hours after oral administration of Zyloric and are much more sustained.</p><p><u>Distribution</u></p><p>Allopurinol is negligibly bound by plasma proteins and therefore variations in protein binding are not thought to significantly alter clearance. The apparent volume of distribution of allopurinol is approximately 1.6 litre/kg which suggests relatively extensive uptake by tissues. Tissue concentrations of allopurinol have not been reported in humans, but it is likely that allopurinol and&nbsp;oxipurinol will be present in the highest concentrations in the liver and intestinal mucosa where xanthine oxidase activity is high.</p><p><u>Biotransformation</u></p><p>The main metabolite of Zyloric is oxipurinol. Other metabolites of allopurinol include allopurinol-riboside and oxipurinol-7-riboside.</p><p><u>Elimination</u></p><p>Approximately 20% of the ingested allopurinol is excreted in the faeces. Elimination of allopurinol is mainly by metabolic conversion to oxipurinol by xanthine oxidase and aldehyde oxidase, with less than 10% of the unchanged drug excreted in the urine. Allopurinol has a plasma half-life of about 0.5 to 1.5 hours.</p><p>Oxipurinol is a less potent inhibitor of xanthine oxidase than allopurinol, but the plasma half-life of oxipurinol is far more prolonged. Estimates range from 13 to 30 hours in man. Therefore effective inhibition of xanthine oxidase is maintained over a 24 hour period with a single daily dose of Zyloric. Patients with normal renal function will gradually accumulate oxipurinol until a steady-state plasma oxipurinol concentration is reached. Such patients, taking 300 mg of allopurinol per day will generally have plasma oxipurinol concentrations of 5-10 mg/litre.</p><p>Oxipurinol is eliminated unchanged in the urine but has a long elimination half-life because it undergoes tubular reabsorption. Reported values for the elimination half-life range from 13.6 hours to 29 hours. The large discrepancies in these values may be accounted for by variations in study design and/or creatinine clearance in the patients.</p><p><u>Pharmacokinetics in patients with renal impairment</u></p><p>Allopurinol and oxipurinol clearance is greatly reduced in patients with poor renal function resulting in higher plasma levels in chronic therapy. Patients with clearance values were between 10 and 20 ml/min, showed plasma oxipurinol concentrations of approximately 30 mg/litre after prolonged treatment with 300 mg allopurinol per day. This is approximately the concentration which would be achieved by doses of 600 mg/day in those with normal renal function. A reduction in the dose of Zyloric is therefore required in patients with renal impairment.</p><p><u>Pharmacokinetics in elderly patients</u></p><p>The kinetics of the drug are not likely to be altered other than due to deterioration in renal function (see section 5.2 Pharmacokinetics in patients with renal impairment).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Mutagenicity</u></p><p>Cytogenetic studies show that allopurinol does not induce chromosome aberrations in human blood cells in vitro at concentrations up to 100 &mu;g/ml and in vivo at doses up to 600 mg/day for a mean period of 40 months.</p><p>Allopurinol does not produce nitroso compounds in vitro or affect lymphocyte transformation in vitro.</p><p>Evidence from biochemical and other cytological investigations strongly suggests that allopurinol has no deleterious effects on DNA at any stage of the cell cycle and is not mutagenic.</p><p><u>Carcinogenicity</u></p><p>No evidence of carcinogenicity has been found in mice and rats treated with allopurinol for up to 2 years.</p><p><u>Teratogenicity</u></p><p>One study in mice receiving intraperitoneal doses of 50 or 100 mg/kg on days 10 or13 of gestation resulted in foetal abnormalities, however in a similar study in rats at 120 mg/kg on day 12 of gestation no abnormalities were observed. Extensive studies of high oral doses of allopurinol in mice up to 100 mg/kg/day, rats up to 200 mg/kg/day and rabbits up to 150 mg/kg/day during days 8 to 16 of the gestation produced no teratogenic effects.</p><p>An in vitro study using foetal mouse salivary glands in culture to detect embryotoxicity indicated that allopurinol would not be expected to cause embryo toxicity without also causing maternal toxicity.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose Monohydrate<br />Maize Starch<br />Povidone<br />Magnesium Stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p><p>Blister Packs: Store in the original package.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Zyloric 100 mg tablets are packed in PVC/aluminium foil blister packs containing 28 or 100 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p><p>Any unused product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Aspen Pharma Trading Limited,
3016 Lake Drive,
Citywest Business Campus,
Dublin 24, Ireland.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                November 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>